Person: ŞİMŞEK, MELİH
3 results
Search Results
Now showing 1 - 3 of 3
Publication Open Access Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study(2022-01-01T00:00:00Z) YASİN, Ayşe İrem; Aydin, Sabin Goktas; SÜMBÜL, BİLGE; KORAL, LOKMAN; ŞİMŞEK, MELİH; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; HACIBEKİROĞLU, İLHAN; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; AKSOY, ASUDE; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; ŞEKER, Mesut; TÜRK, HACI MEHMET; Gumus, Mahmut; YASİN, AYŞE İREM; SÜMBÜL, BİLGE; ŞİMŞEK, MELİH; ŞEKER, MESUT; TÜRK, HACI MEHMETAim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.Publication Metadata only A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer(2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMETIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.Publication Open Access The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer(2022-05-01T00:00:00Z) ŞİMŞEK, MELİH; Yasin, Ayse; BEŞİROĞLU, MEHMET; TOPÇU, Atakan; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, Mesut; TÜRK, HACI MEHMET; ŞİMŞEK, MELİH; BEŞİROĞLU, MEHMET; TOPÇU, ATAKAN; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, MESUT; TÜRK, HACI MEHMETAlthough vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse-transcription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full-dose vaccination. A statistically significant difference in Covid-19 occurrence was found between the patients who had full-dose vaccination or not (p = 0.000). In in-group comparisons of full-dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer-BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid-19 was analyzed, a statistically significant difference was observed between the groups who were full-dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full-dose vaccination (at least two doses of vaccines) should be completed as soon as possible.